ABCB1 p.Glu255Val
[switch to full view]Comments [show]
None has been submitted yet.
PMID: 20720558
[PubMed]
Takahashi N et al: "Influence of CYP3A5 and drug transporter polymorphisms on imatinib trough concentration and clinical response among patients with chronic phase chronic myeloid leukemia."
No.
Sentence
Comment
24
In patients without a CCyR, mutation analysis of the bcr-abl fusion transcript was performed using the Invader assay,31 which detects 25 mutations, including M244V, L248VR, G250E, Q252H, Q252R, Y253F, Y253H, E255K, E255V, E279K, F311L, T315A, T315I, F317L, M351T, F359IV, V379I, L387M, H396P, H396R, S417Y, E459K and F486S.
X
ABCB1 p.Glu255Val 20720558:24:215
status: NEW
PMID: 23103446
[PubMed]
Kosztyu P et al: "Can P-glycoprotein mediate resistance to nilotinib in human leukaemia cells?"
No.
Sentence
Comment
14
Preclinical studies indicated that nilotinib is effective against several Bcr-Abl mutant forms that are found in patients with a diagnosis of Ph+ CML such as E255V, M351T, Q252H/R, Y253F, F317L, and E355G.
X
ABCB1 p.Glu255Val 23103446:14:158
status: NEW
PMID: 23272163
[PubMed]
Singh O et al: "SLC22A1-ABCB1 haplotype profiles predict imatinib pharmacokinetics in Asian patients with chronic myeloid leukemia."
No.
Sentence
Comment
116
Upon further analysis, non-synonymous mutations were detected in the BCR-ABL kinase domain in these two patients - a double mutation at loci G250E and E255V in the former patient and a single mutation at Y253H in the latter patient.
X
ABCB1 p.Glu255Val 23272163:116:151
status: NEW